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not due to CAD. Identiﬁcation and reduction of risk factors is
important in preventing morbidity and mortality due to CAD in
females.
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Objectives: This study sought to compare high intensity statin
versus low intensity statin therapy in Indian patients with ST-
segment elevation myocardial infarction (STEMI) undergoing
thrombolysis.
Background: Previous randomized trials have demonstrated that
statin pre-treatment reduced major adverse cardiac events
(MACEs) in patients with stable angina pectoris and acute coronary
syndrome. However, randomized studies of statin therapy in
Indian patients with STEMI are scarce.
Methods: Of 1230 patients with acute STEMI, 460 patients satisﬁed
the inclusion criteria and were randomized to 80-mg atorvastatin
(n = 225) or 10-mg atorvastatin (n = 235) arms for pre-treatment
before thrombolytic therapy. The primary end point was 30-day
incidence ofMACE including death and nonfatalMI. Secondary end
points included readmission and ST-segment resolution at 90 min
after thrombolysis.
Results: The two groups did not differ in their primary endpoints.
MACE occurred in 12 (5.33%) and 14 (5.96%) patients in the 80-mg
and 10-mg atorvastatin pre-treatment arms, respectively
( p = 0.92). But ST-segment resolution was signiﬁcantly higher in
the 80-mg atorvastatin arm (64.87  14.84 vs 54.84  16.01%,
p < 0.001). Of note, myalgia was signiﬁcantly more in 80 mg statin
group (18.22% vs 7.66%, p = 0.001).
Conclusions: High-dose atorvastatin pre-treatment before
thrombolysis did not show a signiﬁcant difference of MACEs
compared with low dose atorvastatin but did show signiﬁcant
improvement in immediate coronary ﬂow after thrombolysis as
depicted by ST-segment resolution. This beneﬁt at the cost of
subjecting signiﬁcantly greater number of patients to signiﬁcant
myalgia, questions the usefulness of high dose statin in Indian
patients.
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Background: Beta blockers in ST-segment elevation myocardial
infarction (STEMI) are indicated in patients with high heart rates
(HR) or left ventricular (LV) dysfunction. But atrioventricular (AV)
blocks are the biggest concern in inferior MI with beta blockers. In
contrast ivabradine may lower heart rate with a lesser risk of AV
blocks.
Aim: To investigate the feasibility, tolerability, and the efﬁcacy of
ivabradine versusmetoprolol in acute inferior STEMI and during 30
days of follow up.
Methods: It was a prospective double blind single centre rando-
mized controlled study. Of 1032 patients with acute inferior STEMI,
564 patients did not fulﬁll the inclusion criteria and were excluded.
468 patientswere included in the study andwere randomized in 1:1
manner to ivabradine (groupA)andmetoprolol (groupB). 42patients
were lost on follow up and excluded. Per protocol analysis of 426
patients (groupA –210andgroupB –216)wasdone.Theprimaryend
point was 30-days incidence of MACE including death, reinfarction,
complete heart block (CHB), and heart failure. Secondary endpoints
included 30 days incidence of recurrent angina, readmission, ﬁrst or
second degree AV block, and tachyarrhythmias.
Results: Both the drugs decreased the mean heart rate to 62.22
 2.95 (groupA) vs 62.53 3.59 (group B) beats perminute (p = 0.33).
Ejection fraction improved in both the groups (2.4% in group A vs
3.2% in group B). The two groups did not differ signiﬁcantly in their
primary endpoints in terms of death (group A = 1.90% vs group
B = 1.85%, OR = 1.03, 95% CI = 0.25–4.17, p = 0.97), reinfarction (group
A = 0.95% vs group B = 0.93%, OR = 1.03, 95% CI = 0.14–7.37, p = 0.98),
heart failure (group A = 4.76% vs group B = 2.78%, OR = 1.75, 95%
CI = 0.62–4.90, p = 0.29), or CHB (0% vs 2.78%, OR = 0.08, 95%
CI = 0.004–1.37, p = 0.08). There were no signiﬁcant differences in
the secondary end points of recurrent angina, readmission, and
tachyarrhythmias but signiﬁcantly more ﬁrst degree AV blocks
occurred with metoprolol (13.89% vs 2.86%, OR = 5.48, 95%
CI = 2.23–13.47, p = 0.0002).
Conclusions: Ivabradine is well tolerated and equally effective as
metoprolol in acute inferior wall STEMI patients for lowering the
heart rate with signiﬁcant less risk of AV blocks.
Bifurcation stenting – A single center
experience
M. Dhanapal
Bifurcation is the division of an artery into 2 branches and it is a
common anatomical feature of the human coronary tree. Bifurca-
tion lesions are recognized as a common site for atherosclerotic
plaque build up and account for 15–20% of all interventions. These
lesions are complex and challenging for percutaneous intervention.
Numerousanatomicpatternsofbifurcationstenosisarepresentand
there is no consistent and reliable methodology to address these
complex lesions, that is, there is no ‘‘one size ﬁts all’’ solution to the
bifurcationpuzzle.Theoptimalpercutaneouscoronary intervention
technique remains undetermined.
Method:Weanalysed all the bifurcation lesion stenting procedures
done at our institution for three years from 2012 to 2015.
Results: Total of 138 cases of bifurcation stenting was done over a
period of three years. Therewere 96males and 42 females. Anterior
wall myocardial infarction accounted for 89% of all cases and the
remaining were inferior wall myocardial infarctions.
True bifurcation lesions were 53 in number.
86 cases had bifurcation lesion involving the LAD, 45 involved the
LCX, and 7 involved the RCA.
The predominant method of stenting was ‘‘T’’ at provision (TAP)
and involved 91 cases.
12casesunderwent ‘‘Minicrush’’, 8underwentsimultaneouskissing
stent (SKS) technique, and 27 cases underwent Classic T stenting.
Conclusion: The predominant technique of stenting was the TAP
technique,whichwas always followed by proximal optimization of
stent (POTS) to ensure side branch patency. Most of the bifurcation
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lesions can be addressed by this technique thereby reducing the
cost, as a single stent is sufﬁcient and also, the amount of metal at
the bifurcation is reduced, thereby reducing the incidence of rest-
enosis. To conclude TAP is a safe, easy, and cost effective techni-
que that can be used to address most of the bifurcation lesions.
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Background: In the present era of percutaneous coronary inter-
vention (PCI) dual antiplatelet therapy plays a pivotal role. How-
ever there exists inter individual variability in response to
antiplatelet therapy. Thus, monitoring antiplatelet therapy
becomes vital and may identify poor responders who would ben-
eﬁt from the change in therapy.
Objectives: We sought to identify the efﬁcacy of thienopyridine
antiplatelet drugs in post PCI patients, by using AggreGuide A-100
Platelet Aggregometer, point of care device developed to monitor
platelet aggregation using laser scattering technique.
Methods: This prospective, single-center study, includes patients
who received thienopyridine antiplatelet drugs after PCI during
May 2014–January 2015. In these patients, platelet aggregation
inhibition was evaluated from the whole blood sample using
AggreGuide A-100 and expressed in terms of platelet activity index
– PAI. Patients were labelled as poor responders (high on treatment
platelet reactivity) if the PAI was more than 5. Genetic polymorph-
isms of ABCB1 gene were studied in Clopidogrel group.
Results: A total of 405 patients were enrolled in this study. Among
them 109 (26.9%) were female and 296 (83.1%) were males, 108
(26.7%) underwent primary PCI and 297 (83.7%) underwent elective
PCI. At the discretion of treating physician 221 (54.6%), 111 (27.4%),
and 73 (18%) patients received Clopidogrel, Prasugrel, and Tica-
grelor, respectively. It is found that therapy was ineffective
(PAI > 5) in 73 (16%) patients of which 52, 8, and 5 were in Clopido-
grel, Prasugrel, and Ticagrelor groups, respectively. Cumulatively,
there was high PAI in females and those who underwent primary
PCI. In the Clopidogrel group those with additional Cilostazol were
having low PAI ( p < 0.05). Bleeding complicationswere observed in
3, 9, and 3 patients of Clopidogrel, Prasugrel, and Ticagrelor groups,
respectively. Four patients in Clopidogrel group had reinfarction.
Antiplatelet therapy was optimised in those with high PAI.
Conclusion: It is found that there is high resistance to antiplatelet
drugs (especially Clopidogrel), and thus monitoring individual's
platelet reactivity and optimising therapy based on it, should
become anewstandard-of-care for patients on antiplatelet therapy.
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Background: Rapid risk stratiﬁcation of the patient with acute
chest pain is essential to select the best management. Although
culprit lesions in STEMI cluster in the proximal coronary arteries,
their relationship to bifurcations and curvatures, where blood ﬂow
is disturbed, is unknown.
Objective: We investigated the value of the ECG at ﬁrst medical
contact to determine location and size of the ischemic myocardial
area and thereby severity of risk. We also hypothesized that (a)
culprit lesions are mostly localized to areas with disturbed ﬂow,
e.g. distal to bifurcations and curvatures and (b) the distribution of
culprit lesions in the left coronary artery (LCA) and right coronary
artery (RCA) and resulting infarct size are related to the location of
bifurcations and curvatures.
Methods: In patients with ST elevation myocardial infarction
(STEMI), ECG ﬁndings were correlated with the coronary angio-
gram. Using ST-segment deviation patterns the location of the
coronary culprit lesion was predicted and also the size of the
myocardium at risk. By quantitative coronary angiography,
the distances from the vessel ostium, major bifurcations, and
major curvatures to the culprit lesion were measured in 104
patients.
Results: Correct coronary culprit artery identiﬁcation was possible
in 96% of the patients and this wasmost accurate in localization of
culprit lesion in the proximal part of the coronary arteries. Culprit
lesions were located within 20 mm of a bifurcation in 77% of
patients and closer to the bifurcation in the LCA compared with
the RCA (10.13  7.09 vs 18.49  17.16 mm, p = 0.01). Of RCA culprit
lesions, 53% were located within 30 mm of a major curvature.
Compared with those in the RCA, culprit lesions in the LCA were
located more proximally (19.28  10.27 vs 28.77  20.65 mm,
p < 0.01) and were associated with larger myocardial infarctions
as assessed by CK-MB (139.5  139.4 vs 89.2  93.9 unit/L, p = 0.03),
and lower ejection fractions (39.58  7.0% vs 45.16  8.75%,
p = 0.001).
Conclusions: Admission ECG gives adequate insight regarding the
infarct related artery and the location of the lesion in the culprit
vessel. In patients with STEMI, culprit lesions are frequently
located immediately distal to bifurcations and in proximity to
major curvatures where disturbed ﬂow is known to occur. This
supports the role of wall shear stress in the pathogenesis of STEMI
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Background: Uric acid is the end product of nucleotide metabo-
lism. Serum uric acid when elevated is diagnostic of gout
and is a stress marker in hypertension. The correlation of serum
uric acid with coronary artery disease has been evaluated
though in small number cohort. Present study aims to correlate
the serum uric acid with the severity of CAD and as a marker of
CAD.
Materials andmethods: A total of 470 patients consecutively have
been enrolled into the study. The patients with already a diag-
nosis of gout, on long term use of thiazides and those responsible
for elevated serum urate levels were excluded from the study.
The patients enrolled underwent coronary angiography after
informed and written consent. Based on the results of CAG the
patients were divided into two groups, CAD (n = 350) and control
group (n = 120). The severity of CAD was assessed by modiﬁed
Gensini score.
Results: Mean age of presentation in CAD group was 53.72
 10.38 yrs and in controls was 49.60  9.82 yrs ( p < 0.0001). Males
in total cohort were 331 (70.43%). Hypertensives 226 vs 82 ( p = 0.54),
diabetics (161 vs 30, p = 0.60), smokers (209 vs 48, p = 0.64),
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